Lorenzo is the Co-Founder & CEO of GreenBone Ortho srl, a startup founded in 2014 to develop a highly innovative wood-derived, biomimetic and re-absorbable bone implants to repair critical defects in load load bearing and non-loaded bones. Lorenzo has a background in Pharmacology and Business in Innovation, with more than 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Cardinal Health Inc. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008, Lorenzo established collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech start-ups, including SuppreMol GmbH acquired by Baxter International Inc. in 2015. President of Italy HealthCare Licensing Group (Italy HLG) 2010-2014.
Lorenzo Pradella, PhD
Co-Founder and CEO
LYFEBULB-HELSINN
INNOVATION SUMMIT &
AWARD IN ONCOLOGY
Eleven innovators will compete at the Lyfebulb-Helsinn Investment Fund Innovation Summit for the first ever Lyfebulb-Helsinn Investment Fund Innovation Award, which will be presented to an exceptional innovator with outstanding entrepreneurial potential to commercialize creative efforts and ideas to better manage cancer using drugs, medical devices, or consumer products, and healthcare information technologies
THE AWARD
One innovator will be awarded the first Lyfebulb-Helsinn Investment Fund Innovation Award in cancer treatment and cancer supportive care
lyfebulb helsinn 2018 – oncology awards
ABOUT THE AWARD
Monetary grants up to $25K will be awarded to the winners, as well as the opportunity for all finalists to be in a position to be better noticed by venture capital funds
BENEFITS OF THE LYFEBULB-HELSINN INVESTMENT FUND INNOVATION SUMMIT & AWARD
National and international recognition. The benefit for innovators of participating is
the visibility given to the selected 10 finalists, and the Winner in particular
Invitation to the Lyfebulb–Helsinn Innovation Summit 2018 in Monaco as one of 10 Finalists.
The Innovation Summit aims to link innovators with senior leadership from Lyfebulb and Helsinn in order
to spotlight innovators’ efforts and ideas, and provide professional discussion, direction, and inspiration.
The winner will be chosen on March 27, 2018 by a prestigious, international panel.
THE SUMMIT
At this Summit, 10 selected Innovators will compete for
monetary grants and be given the opportunity to be considered for a
possible investment by the Helsinn Investment Fund
ABOUT THE SUMMIT
Beyond presenting their innovative ventures to this group, the 10 finalists will also have a chance to interact and exchange ideas on how to advance further patient innovatorship in the cancer community, engage with Lyfebulb founders, Helsinn Investment Fund leadership, representatives from the patient community, key opinion leaders, and potential investors and compete for a monetary grant.
The Lyfebulb-Helsinn Investment Fund Innovation Summit stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features people who have created a product and a company based on issues encountered because of their personal experiences with a chronic illness.
Patient innovators have a unique ability to create a value-adding disease intervention beyond therapy. Our aim is to support patient-driven innovation and we are laser-focused on improving the quality of life for those living with cancer.
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine and transplantation.
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients
Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions
For more information, visit www.helsinninvestmentfund.com
Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology
Eleven finalists have been selected from a strong roster of talent to compete at the inaugural Lyfebulb-Helsinn Innovation Summit, March 26-27, Monaco
The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies
The award will be presented to the finalist demonstrating outstanding science and entrepreneurial potential to bring their ideas to the market
MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, March 1, 2018:
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The finalists are invited to compete at the Lyfebulb-Helsinn Innovation Summit & Award, which will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.
Due to the high quality and quantity of applications this year, there will be 11 finalists:
Samuel Wagner of Batu Biologics, Inc
Massimo Bocchi of Cellply Srl
Walid Al-Akkad of Engitix Ltd
Gitte Pedersen of Genomic Expression, Inc
Lorenzo Pradella of GreenBone Ortho srl
Samir Housri of Mednet, Inc
Till Erdmann of Myelo Therapeutics GmbH
Christian Apfel of SageMedic, Inc
Aaron Horowitz of Sproutel, Inc
Thierry Desjardins of Surgisafe Ltd
Boaz Gaon of Wisdo Ltd
The Award will recognize outstanding potential among entrepreneurs who have demonstrated an ability to develop and bring to the market innovation designed to improve the quality of life of people with cancer using drugs, medical devices, consumer products and healthcare information technologies. The finalists represent companies of all sizes that have been founded by cancer patients, cancer survivors, or those with close relatives with cancer.
The finalists were selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, Leslie Brille, Chief Investment Officer, Lyfebulb, Riccardo Braglia, Helsinn Group Vice Chairman and CEO and Roberto De Ponti, Head of Corporate New Ventures and Strategic Investments, Helsinn International Services. The Innovation Summit has been founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. A “pitch session” will be held at the summit, where a winner will be selected from the eleven finalists by a panel of experts.
“At Lyfebulb, we interact with numerous individuals who are using their own experiences with chronic disease to originate and develop effective solutions to help others. The level of innovation demonstrated by people who submitted their ideas to the first Lyfebulb-Helsinn Innovation Award were of a very high caliber and we commend all of them. Core to Lyfebulb’s Mission is to empower individuals living with chronic disease, and by embracing patient entrepreneurs and furthering their ideas and businesses, we are doing exactly that.”says Dr. Karin Hehenberger.
Riccardo Braglia added,“I know from experience how a cancer diagnosis can often be a spur towards greater dynamism and entrepreneurship and have seen many examples of great innovation from people who have first-hand experience with the disease. I am looking forward to learning more about the potential of their concepts and am confident that the expertise and industry experience of the judging panel will help choose a finalist who can innovate to improve the lives of people with cancer.”
About Lyfebulb
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.
Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.
About Helsinn Investment Fund S.A., SICAR
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
For more information:
Helsinn Group Media Contact Paola Bonvicini Group Head of Communication Lugano, Switzerland Tel: +41 (0) 91 985 21 21 For more information, please visit www.helsinn.com and follow us onTwitter, LinkedInand Vimeo.
Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD CEO & Founder, Lyfebulb, Phone: + 00 1 917-575-0210 karin@lyfebulb.com www.lyfebulbprod.staging.wpengine.com We are on Twitter. Follow us @Lyfebulb
The Award recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies. Newly appointed jury panel members unveiled Deadline for submissions: January 22, 2018
MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, JANUARY, 9, 2018:Lyfebulb and Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, invite patient entrepreneurs that have embraced and endured the real life experiences of cancer to compete for the Lyfebulb-Helsinn Innovation Award. It has been announced today that:
Carolyn R. “Bo” Aldige, President and Founder of the Prevent Cancer Foundation
Stephen Squinto, PhD, Lyfebulb Chairman and Co-Founder, Venture Partner at Orbimed, and Co-Founder of Alexion
Professor Patrick Rampal, MD, President of the Scientific Center of Monaco
Professor Franco Cavalli, MD, Director of Oncology, Oncology Institute of Southern Switzerland
Professor Françoise Meunier, MD, EORTC Director Special Projects
are the newly-appointed jury panel members of the first Lyfebulb- Helsinn Innovation Award. The Award will recognize outstanding entrepreneurial potential to commercialize innovative efforts and ideas to better manage and improve the quality of life of cancer patients with respect, integrity, and quality, using drugs, medical devices, consumer products and healthcare information technologies. Established companies of all sizes founded by cancer patients, cancer survivors, or those having a close relative with cancer, who have created a product to address issues encountered by cancer patients, are invited to submit applications by January 22, 2018, through the Lyfebulb-Helsinn Innovation Summit & Award website, where more information regarding eligibility and key criteria can also be found.
Ten finalists will be selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, and Mr. Riccardo Braglia, Helsinn Group Vice Chairman and CEO, and invited to compete at the Innovation Summit which will be hosted on 26-27 March 2018, by Helsinn Investment Fund at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco. The Summit is founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. At the summit, the top finalists will be chosen by a panel of experts through a special “pitch session.” In recognition of the best innovative efforts and ideas, a symbolic monetary prize of USD 25’000 will be given to the entrepreneur winner to advance his/her business and use his/her life expertise to help manage the burden of cancer.
“At Lyfebulb, we come into contact with many people who are putting their own experiences with cancer towards developing solutions to help others. Now, for the first time, patient entrepreneurs have the opportunity to receive exposure and financing toward their companies through a targeted event to help them advance their cause,” says Dr. Karin Hehenberger.
Riccardo Braglia added, “Lyfebulb is about encouraging the best in patient entrepreneurship, drawing on the talents of people with first-hand experience of the cancer journey to help develop innovative approaches to cancer supportive care, and this is very much aligned with Helsinn’s journey. We are delighted of the jury panel – their expertise, experience, industry knowledge and dynamism in helping people with cancer will be invaluable.”
About Lyfebulb Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.
See www.lyfebulbprod.staging.wpengine.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About Helsinn Investment Fund The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions. For more information, visit www.helsinninvestmentfund.com
About the Helsinn Group Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information: Helsinn Group Media Contact Paola Bonvicini Group Head of Communication, Helsinn Lugano, Switzerland Tel: +41 (0) 91 985 21 21 Info-hhc@helsinn.com Please visit www.helsinn.com We are on Twitter. Follow us @HelsinnGroup We are on LinkedIn. Follow us @ Helsinn Group
Press Contact for Lyfebulb: Karin Hehenberger, MD, PhD CEO & Founder, Lyfebulb, Phone: + 00 1 917-575-0210 Email: karin@lyfebulb.com Please visit www.lyfebulb.com We are on Twitter. Follow us @Lyfebulb
